Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Apr 12;7(4):e012879.
doi: 10.1136/bmjopen-2016-012879.

Moxibustion versus diclofenac sodium gel for the treatment of knee osteoarthritis: a study protocol for a double-blinded, double-placebo, randomised controlled trial

Affiliations
Randomized Controlled Trial

Moxibustion versus diclofenac sodium gel for the treatment of knee osteoarthritis: a study protocol for a double-blinded, double-placebo, randomised controlled trial

Jian-Ying Zhou et al. BMJ Open. .

Abstract

Introduction: Knee osteoarthritis is a common form of arthritis in elderly patients that is characterised by pain and functional limitation. Moxibustion has been employed to relieve chronic pain as an alternative therapy for knee osteoarthritis. However, the evidence of its efficacy is equivocal due to the low methodological quality in most clinical studies. Therefore, we are performing a double-blinded, double-placebo, randomised controlled trial to evaluate the efficacy of moxibustion in participants with knee osteoarthritis.

Methods and analysis: This is a multicentre, double-blinded, double-placebo, randomised controlled clinical trial. 144 eligible participants with knee osteoarthritis will be randomly assigned to two different groups in a 1:1 ratio. Participants in the moxibustion group will undergo active moxibustion plus placebo gel, whereas participants in the control group will receive diclofenac sodium gel plus placebo moxibustion. Each participant will receive 12 sessions of active/placebo moxibustion at three acupoints (ST35, ST36 and EX-LE4) as well as 2 months of follow-up. Diclofenac sodium gel or placebo gel at a dose of 4 g per knee will be applied three times per day for 4 weeks. The primary outcome measure will be the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score change at the end of the intervention period from baseline. The secondary outcome measures include changes of other subscales (pain, stiffness and function) of WOMAC, visual analogue scale and patient globalassessment. The safety of moxibustion and diclofenac sodium gel will be assessed at every visit.

Ethics and dissemination: This trial has been approved by the Sichuan Regional Ethics Review Committee (permission number: 2015KL-014). The results of this study are expected to provide clinical evidence on the efficacy of moxibustion for pain relief and physical function improvement in patients with knee osteoarthritis. The findings will be submitted for publication in peer-reviewed medical journals and presented at relevant academic conferences.

Trial registration number: NCT02769572.

Keywords: Moxibustion; knee osteoarthritis; randomized controlled trial; study protocol.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Flow chart of the study procedure.
Figure 2
Figure 2
Diagram of the moxibustion device. (A) The components of the device: 1, cylindrical cardboard tube; 2, the base of the device with an adhesive membrane; 3, cylindrical cap; 4, moxa pillar with a magnet at the top. (B) The treatment moxibustion device: 5, the bottom with holes to allow heat and smoke to radiate to the acupoints. (C) The placebo moxibustion device: 6, the bottom with a thermal insulation panel to block smoke and heat; 7, the thermal insulation board.

Similar articles

Cited by

References

    1. Creamer P, Hochberg MC. Osteoarthritis. Lancet 1997;350:503–9. 10.1016/S0140-6736(97)07226-7 - DOI - PubMed
    1. Felson DT. Osteoarthritis of the knee. New Engl J Med 2006;354:841–8. 10.1056/NEJMcp051726 - DOI - PubMed
    1. Xiang YJ, Dai SM. Prevalence of rheumatic diseases and disability in China. Rheumatol Int 2009;29:481–90. 10.1007/s00296-008-0809-z - DOI - PubMed
    1. Mobasheri A. The future of osteoarthritis therapeutics: targeted pharmacological therapy. Curr Rheumatol Rep 2013;15:1–13. 10.1007/s11926-013-0364-9 - DOI - PMC - PubMed
    1. Gamble R, Wyeth-Ayerst J, Johnson EL. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000;43:1905–15. - PubMed

Publication types

Substances

Associated data